MONTHLY REPORT
AUGUST 2026

PENGANA HIGH CONVICTION EQUITIES FUND

DESCRIPTION

The Pengana High Conviction Equities Fund (the Fund) invests globally in a concentrated portfolio of up to 20 stocks. The Fund can invest in both small and large cap stocks and is diversified across countries and sectors. We avoid investment in companies that are currently, in our opinion, unnecessarily harmful to people, animals or the environment.

PERFORMANCE TABLE

NET PERFORMANCE FOR PERIODS ENDING 31 Aug 2026[1]

High Conviction Equities Fund Class A

	1 MTH	1 YEAR	2 YEARS P.A.	3 YEARS P.A.	5 YEARS P.A.	SINCE INCEPTION P.A.
High Conviction Equities Fund Class A	2.8%	-25.6%	0.3%	25.1%	9.5%	21.8%
MSCI World Total Return Index (net, AUD)	0.5%	9.9%	14.8%	16.1%	11.6%	12.8%
RBA Cash Rate plus 3%	0.6%	7.0%	7.0%	7.1%	6.2%	5.1%

High Conviction Equities Fund Class B

	1 MTH	1 YEAR	2 YEARS P.A.	3 YEARS P.A.	5 YEARS P.A.	SINCE INCEPTION P.A.
High Conviction Equities Fund Class B	2.9%	-25.1%	1.4%	25.1%	9.9%	13.7%
MSCI World Total Return Index (net, AUD)	0.5%	9.9%	14.8%	16.1%	11.6%	14.7%
RBA Cash Rate plus 3% p.a.	0.6%	7.0%	7.0%	7.1%	6.2%	5.6%

Net performance figures are shown after all fees and expenses, and assume reinvestment of distributions. Performance figures are calculated using net asset values after all fees and expenses, and assume reinvestment of distributions. No allowance has been made for buy/sell spreads. Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.

Fund inception date Class A: December 2014, Class B July 2020.

PERFORMANCE CHART

NET PERFORMANCE SINCE INCEPTION[2]

Class A



Class B



TOP HOLDINGS (ALPHABETICALLY)

Artrya Limited	Health Care
Brazilian Rare Earths Limited	Materials
Iperionx Ltd.	Materials
Metallium Limited	Materials
OncoSil Medical Ltd	Health Care

SECTOR BREAKDOWN

Health Care	50.9%
Information Technology	2.8%
Materials	42%
Communication Services	1.8%
Options	1.2%
Cash	1.2%

CAPITALISATION BREAKDOWN

Under 5bn USD	97.6%
Derivatives	1.2%
Cash	1.2%

REGION BREAKDOWN

North America	2.8%
Australia/New Zealand	94.7%
Options	1.2%
Cash	1.2%

STATISTICAL DATA

VOLATILITY[3]	NUMBER OF STOCKS	BETA[4]	MAXIMUM DRAW DOWN
28.5%	20	0.97	-40%

AUGUST REPORT

COMMENTARY

- The Fund rose **2.8% in August**, supported by strength in critical minerals companies and positive developments across several major holdings.
- **Metallium** rose 31% after receiving permits for its Texas plant, while **Brazilian Rare Earths** rose 14% following a strong scoping study for its Monte Alto project. **Mesoblast** also gained 15% after reporting results and completing recruitment for its Phase 3 back pain study.
- Biotechnology holdings weighed on performance, with **OncoSil**, **Radiopharm Theranostics** and **Imugene** falling following capital raises, despite regulatory progress or encouraging clinical developments.

The Fund rose 2.8% in August. Critical minerals companies were generally strong during the month after President Trump met mining executives at the White House on 7 August and announced a series of funding packages. Several of our major holdings also reported significant positive developments.

Gold and critical minerals processing company Metallium rose 31% after reporting that it had received permits for chlorine use at its Texas campus, allowing further testing of its reactors. The lack of permits had caused several months of delays, but we expect the plant to be operational early next year. Two further announcements were also significant.

On 10 August, the company announced two board appointments, and its shares rose 12% on the day. Josh Hawes joined as an independent non-executive director, bringing 15 years of experience across critical minerals, commodities and strategic finance. From 2021 to 2023, he served as chief strategy officer at USA Rare Earth, now a core pillar of the US government's rare earth and magnet production strategy and valued at USD5.8 billion.

Kellie Benda also joined as an independent non-executive director with immediate effect. A former investment banker and lawyer, her current positions on the Foreign Investment Review Board and the National Reconstruction Fund Corporation are directly relevant to a company seeking government capital on both sides of the Pacific.

Finally, the company announced a commercial relationship with ASX-listed Environmental Clean Technologies to commercialise a class of nanomaterials known as MXenes. These materials have several potential applications, including as coatings for aircraft and drones to reduce their radar signatures, as well as in superconductors and battery electrodes.

Brazilian Rare Earths rose 14% after releasing a scoping study for its Monte Alto deposit, highlighting world-leading grades of 11.3% TREO (total rare earth oxides). This is more than double the grades of major Western rare earth producers Lynas and MP Materials and should make Monte Alto one of the world's lowest-cost producers.

The project's NPV of USD7.9 billion compares favourably with the company's current market value of USD690 million. Mining companies generally trade at approximately 30% of NPV at the scoping-study stage, implying substantial potential upside in the share price. The cut-off date for the scoping study was February 2026. The company has since released further positive drilling results from Monte Alto, which should increase the project's NPV in future studies.

IperionX rose 3% after announcing that it would redomicile under a Texas-incorporated parent company. We view this positively, as it is likely to assist the company in securing further funding from the US government. On that point we note the US government announced USD450mln of funding for US company Elmet to build a tungsten supply chain. We believe future government grants for reshoring the titanium supply chain are also likely.

The company also announced the appointment of Michael Loparco as an independent non-executive director. Loparco brings 25 years of experience across advanced manufacturing, industrial automation and global supply chains. He was chief executive of automation technology company Symbotic, which has a market capitalisation of USD26 billion, and led it through its US listing in 2022. Before that, he spent more than two decades at Jabil, one of the world's largest outsourced electronics manufacturers.

Stem-cell producer Mesoblast rose 15% after reporting its full-year results and completing recruitment for its Phase 3 back-pain study, which is expected to report results in mid-2027. The company is currently approved and generating sales in a small but high-value rare indication called graft-versus-host disease (GVHD). However, we expect back pain and heart disease to represent much larger, multibillion-dollar opportunities that could transform the company over the coming years.

On the negative side, our biotechnology holdings were generally weak, largely as a result of capital raisings.

Australian pancreatic cancer radiotherapy company OncoSil fell 15% and related options fell 41% despite the company receiving the most significant regulatory approval in its history.

In mid-August, the FDA granted a Humanitarian Device Exemption for unresectable, non-metastatic distal cholangiocarcinoma. OncoSil is the first and only FDA-approved Class III device for this indication, which has an estimated addressable market of AUD80 million.

In September, we exercised some of our options as part of a broader AUD5.6 million capital raising that was also supported by Regal and Australian Ethical.

We continue to expect German government funding for a larger study, which would also allow German hospitals to be reimbursed for using the company's product, providing a further potential catalyst.

The market value of the company is just AUD35mln which we believe greatly undervalues the business given it is now approved in both the US and Europe.

Australian radiotherapy developer Radiopharm Theranostics fell 29% after raising AUD11.9 million in a capital raising in which we participated. The company expects to meet with the FDA on 1 October to discuss the design of a Phase 3 trial for its lead product, RAD101, a radiodiagnostic for metastatic brain cancer.

We expect the company to out-license this asset in the coming months, providing funding for its four therapeutic products. Telix recently gained approval for a product called Pixclara in glioblastoma, a smaller indication with an estimated USD240 million market, compared with the potential USD600 million market for metastatic brain cancer. Telix also plans to conduct a Phase 3 trial in metastatic brain cancer.

The two products have different targeting mechanisms, and it remains unclear which is superior, but we believe there is room in the market for two participants. Radiopharm is 15% owned by Lantheus, a major competitor to Telix. Lantheus is in the process of being acquired by private equity-backed Curium, which may, in turn, become a potential acquirer of Radiopharm.
Australian biotech Imugene fell 20% after raising AUD11 million in a capital raising in which we participated. The company has recently generated encouraging early data in several rare blood cancers, including mantle cell lymphoma and follicular lymphoma. This included two complete responses among five patients treated, all of whom had failed multiple prior lines of therapy.

We expect further data over the coming months which, if positive, should position the company well for a licensing deal. Its current market value is just AUD25 million.

FEATURES

APIR CODE	Class A: HHA0020AU Class B: PCL9196AU
REDEMPTION PRICE	Class A: A$ 3.4932 Class B: A$ 1.5039
FEES *	Management Fee: 1.80% p.a. (Class A) | 1.25% p.a. (Class B) Performance Fee: 15.38% (Class A) | 20% (Class B)
MINIMUM INITIAL INVESTMENT	A$10,000
STRATEGY INCEPTION DATE	11 December 2014
BENCHMARK	RBA Cash Rate + 3%

FUND MANAGERS

James McDonald
Portfolio Manager

Jeremy Bendeich
Portfolio Manager

1. Net performance figures are shown are those of Class A Units, after all fees and expenses and assume reinvestment of distributions. No allowance has been made for buy/sell spreads. Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.
2. Inception 11 December 2014.
3. Annualised standard deviation since inception.
4. Relative to MSCI World. Using daily returns.
* For further information regarding fees please see the PDS available on our website.

PENGANA HIGH CONVICTION EQUITIES FUND

PENGANA CAPITAL LIMITED

ABN 30 103 800 568

AFSL 226566

CLIENT SERVICE

T: +61 2 8524 9900

F: +61 2 8524 9901

E: clientservice@pengana.com

PENGANA CAPITAL GROUP

PENGANA.COM